IRulya Therapeutics Inc. (IRLA) shareholders
Close on Nov 17, 2026Market cap $39.11MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Group One Trading LLC | 5,942,906 | 10.70% | 13G (passive) | Feb 28, 2026 |
| Wilmot B. Harkey Joint filing with Nantahala Capital Management, LLC (9.99%), Daniel Mack (9.99%) | 4,765,862 | 9.99% | 13G (passive) | Jun 30, 2025 |
| David A. Lamond | 4,460,154 | 10.10% | 13D (active) | Mar 4, 2021 |
| Kevin Tang Joint filing with Tang Capital Partners, LP (7.50%), Tang Capital Management, LLC (7.50%) | 3,220,000 | 7.50% | 13G (passive) amendment | Dec 31, 2023 |
| Francesco Micheli Joint filing with Genextra S.p.A. (6.49%), Matteo Bruno Renzulli (6.49%) | 2,806,611 | 6.49% | 13G (passive) amendment | Oct 18, 2024 |
| Karl Naegler Joint filing with Sofinnova Capital VIII (5.40%), Sofinnova Partners SAS, a French corporation (5.40%) and 5 more | 2,397,711 | 5.40% | 13G (passive) | Dec 31, 2024 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (7.20%), Israel A. Englander (7.20%) and 1 more | 1,403,697 | 7.20% | 13G (passive) | Jun 4, 2026 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (8.40%), Perceptive Life Sciences Master Fund, Ltd. (8.40%) | 912,853 | 8.40% | 13G (passive) | Oct 6, 2026 |
| James B. Tananbaum | 652,039 | 6.00% | 13G (passive) | Oct 6, 2026 |
| Cormorant Asset Management, LP Joint filing with Bihua Chen (9.99%) | 108,029 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Dames GP LLC Joint filing with Balyasny Asset Management L.P. (9.99%), Bam Gp LLC (9.99%) and 2 more | 97,699 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Ikarian Capital, LLC Joint filing with Neil Shahrestani (9.00%) | 91,789 | 9.00% | 13G (passive) | Jun 30, 2026 |
| Squadron Master Fund LP Joint filing with Squadron Capital Management LLC (5.60%), Matthew Sesterhenn (5.60%) and 1 more | 55,173 | 5.60% | 13G (passive) | Jul 28, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IRLA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 72,251 | 7.10% | $1.31M | New | 0.14% |
| Millennium Management LLC | 70,779 | 6.96% | $1.29M | New | 0.00% |
| Balyasny Asset Management L.P. | 69,967 | 6.88% | $12.56M | New | 0.02% |
| Squadron Capital Management LLC | 40,375 | 3.97% | $734.42K | New | 0.23% |
| Shay Capital LLC | 17,468 | 1.72% | $329.27K | New | 0.02% |
| Boothbay Fund Management, LLC | 13,911 | 1.37% | $253.04K | New | 0.00% |
| Jane Street Group, LLC | 12,642 | 1.24% | $229.96K | New | 0.00% |
| Vanguard Capital Management LLC | 12,044 | 1.18% | $219.08K | New | 0.00% |
| Cormorant Asset Management, LP | 5,498 | 0.54% | $100.01K | New | 0.01% |
| UBS Group AG | 4,730 | 0.47% | $86.04K | New | 0.00% |
| Morgan Stanley | 4,084 | 0.40% | $74.29K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 3,614 | 0.36% | $65.74K | New | 0.00% |
| BlackRock, Inc. | 1,702 | 0.17% | $30.96K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 567 | 0.06% | $10.31K | New | 0.00% |
| Gen-Wealth Partners Inc | 165 | 0.02% | $3.00K | New | 0.00% |
| Operose Advisors LLC | 159 | 0.02% | $2.89K | New | 0.00% |
| Fortitude Family Office, LLC | 40 | 0.00% | $728 | New | 0.00% |
| Barclays PLC | 27 | 0.00% | $491 | New | 0.00% |
| Integrated Wealth Concepts LLC | 12 | 0.00% | $218 | New | 0.00% |
| Wells Fargo & Company/Mn | 10 | 0.00% | $182 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 27 | 0M | 32.5% | 27 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IRLA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 12,044 | 1.18% | $219.08K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brigette Roberts | Chief Corp. Affairs Officer, Director | – | – | Jun 11, 2026 |
| Dirk Thye | CEO and CMO, Director | 994,885 | 97.82% | Jan 23, 2026 |
| John Militello | Chief Financial Officer | 80,000 | 7.87% | Nov 12, 2026 |
| Keith R. Fandrick | Chief Operating Officer | – | – | Oct 19, 2026 |
| Brendan Hannah | CBO, COO & CCO | 336,547 | 33.09% | Jan 23, 2026 |
| Charles S. Ryan | President | 130,009 | 12.78% | Jan 23, 2026 |
| Catherine M. Bonuccelli | Director | – | – | Nov 12, 2026 |
| Leone D. Patterson | Director | – | – | Nov 12, 2026 |
| John Drayton Wise | Director | – | – | Nov 12, 2026 |
| James Elwood Valentine | Director | – | – | Nov 12, 2026 |
| Christopher J. Senner | Director | 0 | – | Jun 15, 2026 |
| David Lamond | Director | 6,974,754 | 685.77% | Jun 15, 2026 |
| Margaret McLoughlin | Director | 8,000 | 0.79% | Jan 21, 2026 |
| June Bray | Director | – | – | Jan 21, 2026 |
| Luca Benatti | Director | 39,179 | 3.85% | Dec 29, 2025 |
| Rajiv Patni | Director | – | – | Jun 6, 2025 |
| Una S. Ryan | Director | 2,875 | 0.28% | Jun 6, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John Militello Chief Financial Officer | Nov 9, 2026 | Award | +80,000 | – | – | 80,000 |
| Luca Benatti Director | Dec 26, 2025 | Sale | −50,000 | $3.47 | $173.50K | 39,179 |
| Dirk Thye CEO and CMO, Director | Dec 10, 2025 | Gift | +739,885 | – | – | 739,885 |
| Dirk Thye CEO and CMO, Director | Dec 10, 2025 | Gift | −739,885 | – | – | 255,000 |
| Brendan Hannah CBO, COO & CCO | Dec 5, 2025 | Option exercise | +2,271 | $0.55 | $1.25K | 336,547 |
| Brendan Hannah CBO, COO & CCO | Dec 5, 2025 | Option exercise | +25,280 | $0.94 | $23.76K | 361,827 |
| Dirk Thye CEO and CMO, Director | Jun 18, 2025 | Award | +150,944 | $1.20 | $181.13K | 994,885 |
| Charles S. Ryan President | Jun 18, 2025 | Award | +7,548 | $1.20 | $9.06K | 130,009 |
| Brendan Hannah CBO, COO & CCO | Jun 18, 2025 | Award | +37,736 | $1.20 | $45.28K | 334,276 |
| Luca Benatti Director | Oct 23, 2024 | Other | +8,918 | – | – | 89,179 |
| Dirk Thye CEO AND CHIEF MEDICAL OFFICER, Director | Aug 30, 2024 | Buy | +77,000 | $0.70 | $53.90K | 843,941 |
| Dirk Thye CEO AND CHIEF MEDICAL OFFICER, Director | Aug 29, 2024 | Buy | +77,500 | $0.69 | $53.47K | 766,941 |
| Brendan Hannah CHIEF BUSINESS OFFICER AND COO | Aug 21, 2024 | Buy | +5,000 | $0.62 | $3.10K | 272,975 |
| Brendan Hannah CHIEF BUSINESS OFFICER AND COO | Aug 21, 2024 | Buy | +2,280 | $0.61 | $1.39K | 267,975 |
| Brendan Hannah CHIEF BUSINESS OFFICER AND COO | Aug 21, 2024 | Buy | +23,565 | $0.63 | $14.85K | 296,540 |
| Charles S. Ryan PRESIDENT | Aug 20, 2024 | Buy | +48,387 | $0.65 | $31.45K | 122,461 |
| Brendan Hannah CHIEF BUSINESS OFFICER AND COO | Aug 20, 2024 | Buy | +3,424 | $0.60 | $2.05K | 265,695 |
| Brendan Hannah CHIEF BUSINESS OFFICER AND COO | Aug 20, 2024 | Buy | +2,500 | $0.61 | $1.53K | 262,271 |
| Brendan Hannah CHIEF BUSINESS OFFICER AND COO | Aug 19, 2024 | Buy | +2,155 | $0.58 | $1.25K | 259,771 |
| Brendan Hannah CHIEF BUSINESS OFFICER AND COO | Jun 4, 2024 | Option exercise | +56,061 | $0.55 | $30.83K | 257,616 |
| Dirk Thye CHIEF EXECUTIVE OFFICER, Director | Jan 16, 2024 | Option exercise | +90,531 | $0.55 | $49.79K | 539,442 |
| Dirk Thye CHIEF EXECUTIVE OFFICER, Director | Jan 16, 2024 | Option exercise | +149,999 | $0.94 | $141.00K | 689,441 |
| David Lamond Director | Dec 14, 2023 | Buy | +22,627 | $1.04 | $23.53K | 2,347,545 |
| David Lamond Director | Dec 13, 2023 | Buy | +22,627 | $1.00 | $22.63K | 2,324,918 |
| David Lamond Director | Dec 12, 2023 | Buy | +22,327 | $1.02 | $22.77K | 2,302,291 |
| David Lamond Director | Dec 12, 2023 | Buy | +300 | $1.00 | $300 | 2,279,964 |
| David Lamond Director | Dec 7, 2023 | Buy | +19,123 | $1.01 | $19.31K | 2,279,664 |
| David Lamond Director | Dec 6, 2023 | Buy | +19,123 | $1.02 | $19.51K | 2,260,541 |
| David Lamond Director | Dec 5, 2023 | Buy | +19,123 | $1.01 | $19.31K | 2,241,418 |
| David Lamond Director | Dec 1, 2023 | Buy | +14,378 | $0.94 | $13.52K | 2,222,295 |
| David Lamond Director | Nov 30, 2023 | Buy | +14,378 | $0.90 | $12.94K | 2,207,917 |
| David Lamond Director | Nov 29, 2023 | Buy | +14,378 | $0.98 | $14.09K | 2,193,539 |
| David Lamond Director | Aug 31, 2023 | Buy | +41,026 | $1.32 | $54.15K | 2,179,161 |
| David Lamond Director | Aug 30, 2023 | Buy | +41,026 | $1.31 | $53.74K | 2,138,135 |
| David Lamond Director | Aug 17, 2023 | Buy | +24,766 | $1.29 | $31.95K | 2,097,109 |
| David Lamond Director | Aug 16, 2023 | Buy | +117,348 | $1.29 | $151.38K | 2,072,343 |
| David Lamond Director | Aug 15, 2023 | Buy | +107,886 | $1.32 | $142.41K | 1,954,995 |
| Dirk Thye Chief Executive Officer, Director | Aug 10, 2023 | Buy | +88,000 | $1.26 | $110.88K | 448,911 |
| Dirk Thye Chief Executive Officer, Director | Aug 8, 2023 | Buy | +80,000 | $1.24 | $99.20K | 360,911 |
| Brendan Hannah Chief Business Officer | Aug 8, 2023 | Buy | +71,762 | $1.22 | $87.55K | 201,555 |
| Margaret McLoughlin Director | Aug 8, 2023 | Buy | +8,000 | $1.23 | $9.84K | 8,000 |
| Ted Monohon Chief Accounting Officer & VP | Mar 6, 2023 | Sale(10b5-1 plan) | −1,871 | $0.98 | $1.83K | 27,440 |
| Ted Monohon Chief Accounting Officer & VP | Dec 5, 2022 | Tax withholding | −1,640 | $0.72 | $1.18K | 29,311 |
| Ted Monohon Chief Accounting Officer & VP | Sep 6, 2022 | Tax withholding | −1,520 | $1.64 | $2.49K | 30,951 |
| Leslie Holsinger EVP, Preclinical Development | Jun 6, 2022 | Tax withholding | −10,920 | $2.86 | $31.23K | 148,080 |
| Ted Monohon Chief Accounting Officer & VP | Jun 6, 2022 | Tax withholding | −1,529 | $3.12 | $4.77K | 32,471 |
| Caryn Gordon McDowell Chief Legal & Adm. Officer | Jun 6, 2022 | Sale(10b5-1 plan) | −10,800 | $2.86 | $30.89K | 122,500 |
| Caryn Gordon McDowell Chief Legal & Adm. Officer | Jun 6, 2022 | Tax withholding | −6,700 | $2.86 | $19.16K | 133,300 |
| Dirk Thye Chief Executive Officer, Director | May 19, 2022 | Award | +216,322 | – | – | 280,911 |
| Brendan Hannah Chief Business Officer | May 19, 2022 | Award | +113,569 | – | – | 129,793 |
| Karen L. Smith Chief Medical Officer | May 19, 2022 | Award | +170,354 | – | – | 194,690 |
| Philip S. Low Director | May 19, 2022 | Award | +63,974 | – | – | 63,974 |
| Philip S. Low Director | May 19, 2022 | Award | +455,309 | – | – | 455,309 |
| Brendan Hannah Chief Business Officer | May 19, 2022 | Award | +16,224 | – | – | 16,224 |
| Karen L. Smith Chief Medical Officer | May 19, 2022 | Award | +24,336 | – | – | 24,336 |
| Dirk Thye Chief Executive Officer, Director | May 19, 2022 | Award | +64,589 | – | – | 64,589 |
| David Lamond Director | May 19, 2022 | Award | +200,002 | – | – | 1,734,722 |
| Christopher P. Lowe Interim CEO, COO & CFO | Mar 3, 2022 | Award | +175,000 | – | – | 265,000 |
| Ted Monohon Chief Accounting Officer & VP | Mar 3, 2022 | Award | +34,000 | – | – | 34,000 |
| Caryn Gordon McDowell Chief Legal & Adm. Officer | Mar 3, 2022 | Award | +140,000 | – | – | 140,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of IRulya Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,885 shares on Oct 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Blue Devil Trust Former Board Member | Nov 5, 2026 | 3,471 | $103.53K | Oct 9, 2026 | Open Market |
| Dirk Thye Officer | Oct 21, 2026 | 3,700 | $133.33K | Oct 21, 2026 | RSU |
| Luca Benatti OFFICER | Dec 29, 2025 | 50,000 | $173.21K | Dec 26, 2025 | RSU |
See a number that looks wrong?